<- Go Home
Baxalta Incorporated
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets products for the treatment of hemophilia, immunology, and oncology. It provides products for the treatment of bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiencies, burns, shock, and other chronic and acute medical conditions, as well as acute lymphoblastic leukemia. The company offers ADVATE, a recombinant factor VIII therapy for the treatment of children and adults with hemophilia A; FEIBA, an inhibitor management therapy; and GAMMAGARD LIQUID, a liquid formulation of the antibody-replacement therapy for the treatment of primary immunodeficiency. Baxalta Incorporated was incorporated in 2014 and is based in Bannockburn, Illinois with additional offices in Zug, Switzerland; Westlake Village and Newbury Park, California; Lexington, Massachusetts; and Chicago, Illinois. Baxalta Incorporated operates as a subsidiary of Dyax Corp.
Market Cap
$31.5B
Volume
5.8M
Cash and Equivalents
$911.0M
EBITDA
$2.1B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$3.9B
Profit Margin
61.59%
52 Week High
$46.52
52 Week Low
$29.83
Dividend
N/A
Price / Book Value
7.45
Price / Earnings
38.69
Price / Tangible Book Value
15.58
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
$1.9B
Return on Equity
15.32%
Return on Assets
10.65
Cash and Short Term Investments
$911.0M
Debt
$5.6B
Equity
$4.2B
Revenue
$6.3B
Unlevered FCF
$65.8M
Sector
Biotechnology
Category
N/A